Lan Nguyen Phu Huong, Hien Nguyen Huu, Le Thi Phuong Tu, Thanh Duy Pham, Thieu Nga Tran Vu, Ngoc Dung Tran Thi, Tuyen Ha Thanh, Vinh Phat Voong, Ellington Matthew J, Thwaites Guy E, Van Vinh Chau Nguyen, Baker Stephen, Boinett Christine J
The Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam.
Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.
Antimicrob Resist Infect Control. 2017 Oct 16;6:105. doi: 10.1186/s13756-017-0265-1. eCollection 2017.
Broad-spectrum antimicrobials are commonly used as empirical therapy for infections of presumed bacterial origin. Increasing resistance to these antimicrobial agents has prompted the need for alternative therapies and more effective surveillance. Better surveillance leads to more informed and improved delivery of therapeutic interventions, potentially leading to better treatment outcomes.
We screened 1017 Gram negative bacteria (excluding spp. and spp.) isolated between 2011 and 2013 from positive blood cultures for susceptibility against third generation cephalosporins, ESBL and/or AmpC production, and associated ESBL/AmpC genes, at the Hospital for Tropical Diseases in Ho Chi Minh City.
Phenotypic screening found that 304/1017 (30%) organisms were resistance to third generation cephalosporins; 172/1017 (16.9%) of isolates exhibited ESBL activity, 6.2% (63/1017) had AmpC activity, and 0.5% (5/1017) had both ESBL and AmpC activity. and spp. were the most common organisms associated with ESBL and AmpC phenotypes, respectively Nearly half of the AmpC producers harboured an ESBL gene. There was no significant difference ( > 0.05) between the antimicrobial resistance phenotypes of the organisms associated with community and hospital-acquired infections.
AmpC and ESBL producing organisms were commonly associated with bloodstream infections in this setting, with antimicrobial resistant organisms being equally distributed between infections originating from the community and healthcare settings. spp., which was associated with bloodstream infections in cirrhotic/hepatitis patients, were the most abundant AmpC producing organism. We conclude that empirical monotherapy with third generation cephalosporins may not be optimum in this setting.
广谱抗菌药物常用于对推测为细菌源性感染的经验性治疗。对这些抗菌药物耐药性的增加促使人们需要替代疗法和更有效的监测。更好的监测有助于更明智地提供治疗干预措施,并可能改善治疗效果。
我们对2011年至2013年间从胡志明市热带病医院的阳性血培养物中分离出的1017株革兰氏阴性菌(不包括某些菌属)进行了第三代头孢菌素敏感性、ESBL和/或AmpC产生情况以及相关ESBL/AmpC基因的筛查。
表型筛查发现,304/1017(30%)的菌株对第三代头孢菌素耐药;172/1017(16.9%)的分离株表现出ESBL活性,6.2%(63/1017)具有AmpC活性,0.5%(5/1017)同时具有ESBL和AmpC活性。某些菌属分别是与ESBL和AmpC表型相关的最常见菌属。近一半产生AmpC的菌株携带ESBL基因。社区获得性感染和医院获得性感染相关菌株的抗菌药物耐药表型之间无显著差异(P>0.05)。
在这种情况下,产生AmpC和ESBL的菌株通常与血流感染相关,抗菌药物耐药菌株在社区感染和医疗机构感染中分布均匀。在肝硬化/肝炎患者血流感染中相关的某些菌属是最常见的产生AmpC的菌属。我们得出结论,在这种情况下,第三代头孢菌素的经验性单药治疗可能并非最佳选择。